PATENT CLAIM ANALYSIS

Application Number: 15927170
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-11
Patent Classification: ["514", "230500"]

Abstract:
The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.

Claim (Index 97):
The method of  claim 1 , wherein the autoimmune or inflammatory disease is selected from allergy, allergic rhinitis, arthritis, asthma, chronic obstructive pulmonary disease, degenerative joint disease, dermatitis, organ rejection, eczema, hepatitis, inflammatory bowel disease, multiple sclerosis, myasthenia gravis, psoriasis, sepsis, sepsis syndrome, septic shock, systemic lupus erythematosus, tissue graft rejection, type I diabetes.

Metadata:
- Claim Count in Document: 126.0
- Percentile: 90.0
- Lexical Diversity: 1.31034
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14554306', '15354223', '15088373', '14554263', '15906163']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8597784289680919
- 35 USC 102 Novelty (BERT): 0.5819785804687384
- Combined Prediction Score: 0.8319984441181565
- Mean Citation Score: 555.065632
- Max Citation Score: 614.763
- Similarity Product: 374.1179152252078

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test